

Electronic Acknowledgement Receipt

EFS ID:	5889009
Application Number:	10524963
International Application Number:	
Confirmation Number:	3567
Title of Invention:	N-(-3-Methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl-phenyl) pyridine-3- sulphonamide as an anticancer agent
First Named Inventor/Applicant Name:	David William Tonge
Customer Number:	44992
Filer:	Jacob G. Weintraub
Filer Authorized By:	
Attorney Docket Number:	100815-1P US
Receipt Date:	14-AUG-2009
Filing Date:	18-FEB-2005
Time Stamp:	12:26:36
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	7868
Deposit Account	503231
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	IDSreferences.pdf	52353	no	1
			f15ebebb4f3d2313f8b74f9ddfe3466c5e49752d		
Warnings:					
Information:					
2	Foreign Reference	WO1996040681.pdf	5637755	no	109
			c1a41052baac37515cd0727a4ba1f458e9cde77		
Warnings:					
Information:					
3	Foreign Reference	WO2001044239.pdf	10694791	no	295
			238fad4fd00b9d1ce78ec7f2c8b39acd3846a4ce		
Warnings:					
Information:					
4	Foreign Reference	WO2002049630.pdf	863748	no	17
			e1142d18ffea7809c4736b13c307ce2a055d83b		
Warnings:					
Information:					
5	Foreign Reference	WO2001060370Japanese.pdf	1168916	no	27
			3839e7b203f3d44cc3687f7f080ad15ea71adec1		
Warnings:					
Information:					
6	NPL Documents	EndothelinreceptorAntagonist1.pdf	50213	no	1
			2d442a29a7e44f08da7589a1e1df1b44ad701e99		
Warnings:					
Information:					
7	NPL Documents	Theroleofendothelin1andendothelin1.pdf	324726	no	4
			6482ccb7622179fc2457a8a678be3e3aec7a7c64		
Warnings:					
Information:					
8	NPL Documents	ABT627anendothelinETreptorselective1.pdf	718919	no	7
			d23fd65e1035e2397c7a39965b255cf11e75e277		
Warnings:					
Information:					

9	NPL Documents	DatabaseWPISetionChWeek200163.pdf	97747 87651590d299345ff1bea3256038435b51bf0795	no	2
Warnings:					
Information:					
10	Miscellaneous Incoming Letter	100815Declaration.pdf	113901 29c70d4e7b48bb2cbcd3488a25a480949fd1cdfc	no	3
Warnings:					
Information:					
11	Miscellaneous Incoming Letter	100815Postcard.pdf	17404 1d30b61cacc96610980fe708d787b8dc7afbe4b6	no	1
Warnings:					
Information:					
12	Information Disclosure Statement (IDS) Filed (SB/08)	IDS2.pdf	926688 03a133b221d45ddd7b662d8185401dbb701e2526	no	4
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
13	NPL Documents	SafetyandEfficacyoftheSpecificEndothelin.pdf	1023750 b3c9d352880f965c11f90666f5e944784e936731	no	12
Warnings:					
Information:					
14	NPL Documents	SpecificEndothelin-AREceptorAntagonism.pdf	93104 647aa69e21c25b3b6ea4c49ec1d0092f25614e75	no	3
Warnings:					
Information:					
15	NPL Documents	Newendothelin-Areceptorantagonistprolongssurvival.pdf	51130 ea6ab06b61d10e1b2a0e5fa33381b87d2a85c62a	no	1
Warnings:					
Information:					
16		100815AmendementandResponse.pdf	68912 1c4113ef7a8f17f94744fc4262a7a6ce0a3b9d90	yes	11
Multipart Description/PDF files in .zip description					
	Document Description		Start	End	

	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Claims	2	3
	Applicant Arguments/Remarks Made in an Amendment	4	11

Warnings:

Information:

17	Fee Worksheet (PTO-875)	fee-info.pdf	30609	no	2
			bf7c83d2cec9d0e91ffa4da7e680fdb0afaffl		

Warnings:

Information:

Total Files Size (in bytes):	21934666
-------------------------------------	----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.